Fane, Mitchell E.
Chhabra, Yash
Alicea, Gretchen M.
Maranto, Devon A.
Douglass, Stephen M.
Webster, Marie R. http://orcid.org/0000-0001-7633-7150
Rebecca, Vito W.
Marino, Gloria E.
Almeida, Filipe
Ecker, Brett L.
Zabransky, Daniel J. http://orcid.org/0000-0002-8184-3346
Hüser, Laura
Beer, Thomas
Tang, Hsin-Yao http://orcid.org/0000-0003-1838-018X
Kossenkov, Andrew
Herlyn, Meenhard http://orcid.org/0000-0003-0839-0739
Speicher, David W.
Xu, Wei
Xu, Xiaowei
Jaffee, Elizabeth M. http://orcid.org/0000-0003-3841-6549
Aguirre-Ghiso, Julio A.
Weeraratna, Ashani T. http://orcid.org/0000-0003-0448-6952
Article History
Received: 17 August 2020
Accepted: 19 April 2022
First Online: 1 June 2022
Change Date: 7 August 2023
Change Type: Clarification
Change Details: Editor’s Note: Readers are alerted that the reliability of some of the data presented in this manuscript is currently in question. Appropriate editorial action will be taken once this matter is resolved
Competing interests
: J.A.A.-G. is a scientific co-founder of, scientific advisory board member of, equity owner in and receives financial compensation as a consultant for HiberCell, a Mount Sinai spin-off company that is focused on therapeutics that prevent or delay the recurrence of cancer. A.T.W. is on the board of reGAIN Therapeutics. E.M.J. reports other support from Abmeta, personal fees from Genocea, personal fees from Achilles, personal fees from DragonFly, personal fees from Candel Therapeutics, other support from the Parker Institute, grants and other support from Lustgarten, personal fees from Carta, grants and other support from Genentech, grants and other support from AstroZeneca, personal fees from NextCure and grants and other support from Break Through Cancer outside of the submitted work.